{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T13:49:45Z","timestamp":1778248185171,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004470","name":"Daewoong Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004470","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00210-025-04932-z","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T07:05:33Z","timestamp":1766819133000},"page":"8263-8269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of formulation on the pharmacokinetics, safety, and tolerability of enavogliflozin in healthy Korean adults"],"prefix":"10.1007","volume":"399","author":[{"given":"Soyoung","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Jin","family":"Nah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wonsuk","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anhye","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyounggyoon","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,27]]},"reference":[{"key":"4932_CR1","doi-asserted-by":"publisher","unstructured":"Amawi RM et al (2022) Understanding color associations and their effects on expectations of drugs\u2019 efficacies. Pharmacy. https:\/\/doi.org\/10.3390\/pharmacy10040082","DOI":"10.3390\/pharmacy10040082"},{"key":"4932_CR2","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2018) 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142018. Diabetes Care 41(Supplement_1): S73-S85","DOI":"10.2337\/dc18-S008"},{"issue":"9","key":"4932_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0238378","volume":"15","author":"O Blazhenkova","year":"2020","unstructured":"Blazhenkova O et al (2020) The shape of the pill: perceived effects, evoked bodily sensations and emotions. PLoS ONE 15(9):e0238378","journal-title":"PLoS ONE"},{"issue":"1","key":"4932_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2337\/diaclin.32.1.4","volume":"32","author":"EC Chao","year":"2014","unstructured":"Chao EC (2014) SGLT-2 inhibitors: a new mechanism for glycemic control. Clin Diabetes 32(1):4\u201311","journal-title":"Clin Diabetes"},{"issue":"7","key":"4932_CR5","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.clinthera.2015.04.015","volume":"37","author":"X Chen","year":"2015","unstructured":"Chen X et al (2015) Pharmacokinetics, pharmacodynamics, and safety of single-dose canagliflozin in healthy Chinese subjects. Clin Ther 37(7):1483-1492 e1","journal-title":"Clin Ther"},{"issue":"3","key":"4932_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12030268","volume":"12","author":"M-K Choi","year":"2020","unstructured":"Choi M-K et al (2020) Comparative pharmacokinetics and pharmacodynamics of a novel sodium-glucose cotransporter 2 inhibitor, DWP16001, with dapagliflozin and ipragliflozin. Pharmaceutics 12(3):268","journal-title":"Pharmaceutics"},{"issue":"13","key":"4932_CR7","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s40265-021-01573-3","volume":"81","author":"L Del Vecchio","year":"2021","unstructured":"Del Vecchio L et al (2021) A role for SGLT-2 inhibitors in treating non-diabetic chronic kidney disease. Drugs 81(13):1491\u20131511","journal-title":"Drugs"},{"issue":"1","key":"4932_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","volume":"14","author":"R Grempler","year":"2012","unstructured":"Grempler R et al (2012) Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14(1):83\u201390","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"4932_CR9","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.2337\/dci24-0103","volume":"48","author":"WH Herman","year":"2025","unstructured":"Herman WH et al (2025) Is screening for heart failure and peripheral artery disease warranted in asymptomatic adults with diabetes? A perspective on the 2025 American Diabetes Association \u201cStandards of Care in Diabetes.\u201d Diabetes Care 48(9):1465\u20131471","journal-title":"Diabetes Care"},{"issue":"9","key":"4932_CR10","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.1111\/bcp.15348","volume":"88","author":"JG Hwang","year":"2022","unstructured":"Hwang JG et al (2022) Dose-dependent glucosuria of DWP16001, a novel selective sodium\u2013glucose cotransporter-2 inhibitor, in healthy subjects. Br J Clin Pharmacol 88(9):4100\u20134110","journal-title":"Br J Clin Pharmacol"},{"key":"4932_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15632","author":"SI Jeong","year":"2023","unstructured":"Jeong SI et al (2023) Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium\u2013glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults. Br J Clin Pharmacol. https:\/\/doi.org\/10.1111\/bcp.15632","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"4932_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12090865","volume":"12","author":"J-H Kim","year":"2020","unstructured":"Kim J-H et al (2020) In vitro metabolism of DWP16001, a novel sodium-glucose cotransporter 2 inhibitor, in human and animal hepatocytes. Pharmaceutics 12(9):865","journal-title":"Pharmaceutics"},{"issue":"4","key":"4932_CR13","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1111\/bcp.15613","volume":"89","author":"B Kim","year":"2023","unstructured":"Kim B et al (2023) Pharmacokinetic and pharmacodynamic interaction between DWP16001, an sodium\u2013glucose cotransporter 2 inhibitor and metformin in healthy subjects. Br J Clin Pharmacol 89(4):1462\u20131470","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"4932_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2133\/dmpk.DMPK-11-RV-111","volume":"27","author":"K Kurose","year":"2012","unstructured":"Kurose K et al (2012) Population differences in major functional polymorphisms of pharmacokinetics\/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet 27(1):9\u201354","journal-title":"Drug Metab Pharmacokinet"},{"key":"4932_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15046","author":"SH Kwak","year":"2023","unstructured":"Kwak SH et al (2023) Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: a 24\u2010week, multicentre, randomized, double\u2010blind, placebo\u2010controlled, phase III trial. Diabetes Obes Metab. https:\/\/doi.org\/10.1111\/dom.15046","journal-title":"Diabetes Obes Metab"},{"issue":"20","key":"4932_CR16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013389","volume":"8","author":"CS Lam","year":"2019","unstructured":"Lam CS et al (2019) SGLT\u20102 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects. J Am Heart Assoc 8(20):e013389","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"4932_CR17","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/cts.12771","volume":"13","author":"C Lo","year":"2020","unstructured":"Lo C et al (2020) Pharmacogenomics in Asian subpopulations and impacts on commonly prescribed medications. Clin Transl Sci 13(5):861\u2013870","journal-title":"Clin Transl Sci"},{"key":"4932_CR18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3389\/fphar.2014.00274","volume":"5","author":"Y Lu","year":"2014","unstructured":"Lu Y et al (2014) Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans. Front Pharmacol 5:274","journal-title":"Front Pharmacol"},{"issue":"17","key":"4932_CR19","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v7.i17.354","volume":"7","author":"JJ Mar\u00edn-Pe\u00f1alver","year":"2016","unstructured":"Mar\u00edn-Pe\u00f1alver JJ et al (2016) Update on the treatment of type 2 diabetes mellitus. World J Diabetes 7(17):354","journal-title":"World J Diabetes"},{"issue":"4","key":"4932_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5897\/JPAP2013.0001","volume":"4","author":"J Ozougwu","year":"2013","unstructured":"Ozougwu J et al (2013) The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. J Physiol Pathophysiol 4(4):46\u201357","journal-title":"J Physiol Pathophysiol"},{"issue":"6","key":"4932_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14061210","volume":"14","author":"M Pang","year":"2022","unstructured":"Pang M et al (2022) Pharmacokinetics and tissue distribution of enavogliflozin in mice and rats. Pharmaceutics 14(6):1210","journal-title":"Pharmaceutics"},{"issue":"1","key":"4932_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41371-020-00393-4","volume":"35","author":"A Piperidou","year":"2021","unstructured":"Piperidou A, Loutradis C, Sarafidis P (2021) SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives. J Hum Hypertens 35(1):12\u201325","journal-title":"J Hum Hypertens"},{"issue":"4","key":"4932_CR23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.7326\/M16-1860","volume":"166","author":"A Qaseem","year":"2017","unstructured":"Qaseem A et al (2017) Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 166(4):279\u2013290","journal-title":"Ann Intern Med"},{"issue":"6","key":"4932_CR24","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/ehjcvp\/pvac001","volume":"8","author":"V Razuk","year":"2022","unstructured":"Razuk V et al (2022) SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother 8(6):557\u2013567","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"11","key":"4932_CR25","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1002\/jcb.26097","volume":"118","author":"K Rehman","year":"2017","unstructured":"Rehman K, Akash MSH (2017) Mechanism of generation of oxidative stress and pathophysiology of type 2 diabetes mellitus: how are they interlinked? J Cell Biochem 118(11):3577\u20133585","journal-title":"J Cell Biochem"},{"key":"4932_CR26","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.foodqual.2015.06.009","volume":"45","author":"X Wan","year":"2015","unstructured":"Wan X et al (2015) Assessing the expectations associated with pharmaceutical pill colour and shape. Food Qual Prefer 45:171\u2013182","journal-title":"Food Qual Prefer"},{"key":"4932_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15080","author":"YS Yang","year":"2023","unstructured":"Yang YS et al (2023) Efficacy and safety of monotherapy with enavogliflozin in Korean patients with type 2 diabetes mellitus: results of a 12\u2010week, multicentre, randomized, double\u2010blind, placebo\u2010controlled, phase 2 trial. Diabetes Obes Metab. https:\/\/doi.org\/10.1111\/dom.15080","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"4932_CR28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrendo.2017.151","volume":"14","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Ley SH, Hu FB (2018) Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 14(2):88\u201398","journal-title":"Nat Rev Endocrinol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04932-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04932-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04932-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T02:39:37Z","timestamp":1776393577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04932-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,27]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4932"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04932-z","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,27]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}